Paul Tudor Jones's AUPH Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 63,138 shares of Aurinia Pharmaceuticals Inc. (AUPH) worth $1.01 M, representing 0.00% of the portfolio. First purchased in 2021-Q3, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in AUPH, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 65,964 shares. Largest reduction occurred in Q2 2023, reducing 105,952 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Aurinia Pharmaceuticals (AUPH) Holding Value Over Time
Track share changes against reported price movement
Quarterly Aurinia Pharmaceuticals (AUPH) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -2,826 | Reduce 4.28% | 63,138 | $15.95 |
| Q3 2025 | +65,964 | New Buy | 65,964 | $11.05 |
| Q2 2024 | -14,954 | Sold Out | 0 | $0.00 |
| Q1 2024 | +14,954 | New Buy | 14,954 | $5.01 |
| Q4 2023 | -13,533 | Sold Out | 0 | $0.00 |
| Q3 2023 | +13,533 | New Buy | 13,533 | $7.77 |
| Q2 2023 | -105,952 | Sold Out | 0 | $0.00 |
| Q1 2023 | +64,113 | Add 153.24% | 105,952 | $0.01 |
| Q4 2022 | +41,839 | New Buy | 41,839 | $0.00 |
| Q3 2022 | -62,369 | Sold Out | 0 | $0.00 |
| Q2 2022 | +62,369 | New Buy | 62,369 | $10.05 |
| Q1 2022 | -31,176 | Sold Out | 0 | $0.00 |
| Q4 2021 | +15,176 | Add 94.85% | 31,176 | $22.87 |
| Q3 2021 | +16,000 | New Buy | 16,000 | $22.12 |
Paul Tudor Jones's Aurinia Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Aurinia Pharmaceuticals Inc. (AUPH) in Q3 2021, acquiring 16,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Aurinia Pharmaceuticals Inc. (AUPH) for 14 quarters since Q3 2021.
Paul Tudor Jones's largest addition to Aurinia Pharmaceuticals Inc. (AUPH) was in Q3 2025, adding 65,964 shares worth $728,902.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 63,138 shares of Aurinia Pharmaceuticals Inc. (AUPH), valued at approximately $1.01 M.
As of the Q4 2025 filing, Aurinia Pharmaceuticals Inc. (AUPH) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Aurinia Pharmaceuticals Inc. (AUPH) was 105,952 shares, as reported at the end of Q1 2023.